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Colorectal cancer (CRC) is a common malignancy. Estimated new
CRC cases rank as the second most common cancer in women and
men in France (12). In a subset of cases, an autosomal dominantly
inherited susceptibility to CRC has been identified as being
responsible for hereditary non-polyposis colorectal cancer
(HNPCC) (reviewed in Lynch and Smyrk, 1996). The HNPCC
syndrome is characterized by early age of CRC onset, predomi-
nance of proximal and multiple tumours (Lynch and Smyrk,
1996). In 1990, the International Collaborative Group (ICG-
HNPCC) proposed minimum criteria to be used for selection of
families for research collaborative study for the identification of
the HNPCC predisposing genes: (i) at least three relatives should
have histologically verified CRC and one of them should be a
first-degree relative to the other two; (ii) at least two successive
generations should be affected; and (iii) in one of the relatives,
CRC should be diagnosed under 50 years of age (Vasen et al,
1991). This definition did not include extracolonic cancers, mainly
cancers of the endometrium, ovaries, stomach and upper urologic
tracts, shown now to be part of the HNPCC tumour spectrum by
epidemiological (Lynch et al, 1988; Watson and Lynch, 1993;
Benatti et al, 1993; Vasen et al, 1990) and molecular studies
(Vasen et al, 1996). Extracolonic cancers have been recently
included in new guidelines (Bethesda guidelines) for testing of
colorectal tumours for microsatellite instability (Rodriguez-Bigas
et al, 1997). The exact frequency of HNPCC is currently
unknown; estimates range from 1 to 5% (Lynch and Smyrk, 1996;
Aaltonen et al, 1998).
In the past years, germline mutations in six different genes
(hMSH2, hMLH1, hPMS1, hPMS2, GTBP/hMSH6 and TGFbRII)
were shown to be responsible for predisposition to colorectal
cancers in either HNPCC families (Fishel et al, 1993; Leach et al,
1993; Bronner et al, 1994; Papadopoulos et al, 1994; Nicolaides et
al, 1994; Miyaki et al, 1997; Lu et al, 1998), families with incom-
plete criteria (Moslein et al, 1996; Akiyama et al, 1997; Wang et
al, 1997) or patients having developed sporadic CRC before the
age of 35 (Liu et al, 1995a). Five of these genes encode proteins
involved in the DNA repair pathway (Prolla et al, 1994; Fishel et
al, 1994; Drummond et al, 1995). Except in rare cases (Nicolaides
et al, 1998), the mechanism leading to deficiency in DNA
mismatch repair (MMR) is recessive and involves ‘two hits’:
HNPCC patients inherit a mutated allele, then a second somatic
genetic or epigenetic event occurs on the wild-type allele during
the development of the tumour (Hemminki et al, 1994; Konishi et
al, 1996). Through the recognition and repair of incorrectly paired
nucleotides, these cancer-susceptibility genes encode cellular
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and therefore belong to the ‘caretakers’ category (Kinzler and
Vogelstein, 1997).
HNPCC patients develop CRC at a young age (average age of
44) (Lynch and Smyrk, 1996). Gene-carriers have a lifetime risk of
80% of developing CRC (Vasen et al, 1996) and adapted clinical
surveillance should be recommended to maximize detection of
early-stage and premalignant lesions in the principal organ sites
affected in the HNPCC families (Lynch et al, 1996; Weber, 1996).
MMR gene-carriers may also be offered the option of prophylactic
subtotal colectomy (Lynch and Smyrk, 1996). Recent data indicate
that loss of DNA MMR function might be predictive of tumoural
response to chemotherapeutic agents (Aebi et al, 1996). For all
these reasons, it is of great clinical importance to accurately iden-
tify such high-risk people.
In order to identify such patients, we performed combined mole-
cular approaches among three different groups: HNPCC kindreds
fulfilling the ICG criteria (n = 10), families in which at least one of
the criteria was not satisfied (n = 7) and apparently sporadic CRC
cases diagnosed before the age of 50 (n = 17). Our results suggest
that MSI and absence of p53 protein accumulation in tumour are
predictive of familial and probably hereditary CRC cases. In addi-
tion, the study of MS status combined with hMSH2 and hMLH1
protein immunostaining performed on tumoural tissues represents a
low-cost discriminating test for selecting CRC cases with the
highest probability to have an MMR-gene germline defect.
MATERIALS AND METHODS
Family and patient selection
Thirty-four white patients with CRC were selected for the study,
with their written informed consent. Group 1 (n = 10) represented
patients fulfilling the ICG criteria for HNPCC. In group 2 (n = 7),
patients were classified as incomplete HNPCC, because they had a
strong family history of CRC, but were missing at least one ICG
criterion. Group 3 (n = 17) represented a clinic-based population
prospectively selected solely upon the criterion of age being below
50 years at diagnosis of the CRC (range 17–50, mean 36), after
verification of the absence of any CRC and tumours from the
HNPCC spectrum recorded in their families up to the second
degree. All cancers were histologically verified.
Tissue samples and DNA preparation
Frozen or paraffin-embedded tissues were examined microscopi-
cally for determination of exact tumour and normal mucosa local-
ization. DNA was prepared from tumoural tissue samples after
dissection upon the histological analysis. Germinal DNA was
obtained from peripheral blood mononuclear cells drawn at the
same time that cancer tissue was obtained.
Analysis of microsatellite instability
Paired normal and tumoural DNA was analysed for each patient
for microsatellite instability with a set of 20 microsatellite
markers, dinucleotide (CA)n repeats: D2S116, D2S117, D2S119,
D2S123, D2S147, D2S155, D2S391, D3S1277, D3S1298,
D3S1561, D5S82, D5S299, CA7, D5S346, D7S481, D7S517,
D7S531, D11S904, D13S175, D20S116 (Gyapay et al, 1994). In
addition, three mononucleotide (A)n repeats were investigated as
previously described, BAT-40 (Liu et al, 1996), BAT-26 (Parsons
et al, 1995) and BAT-RII (Parsons et al, 1995). Polymerase chain
reaction (PCR) reaction mix (20 ml) contained 100 ng of DNA
(extracted from lymphocytes or tumour), 0.15 mM of each primer,
5 mM of each dNTP, [a-33P]-dATP, 1.25 mM magnesium chloride
(MgCl2), 1 ´ PCR buffer, 0.5 U Taq Polymerase (Perkin-Elmer).
PCR was performed as follows: one initial denaturing step at 95°C
for 5 min; 30 cycles at 95°C (30 s), 55°C (30 s) and 72°C (30 s); a
final extension step at 72°C for 10 min. PCR products were diluted
with formamide dye solution, followed by denaturation at 95°C 
(2 min). Four microlitres of each diluted sample were loaded on
8% polyacrylamide and 7-M urea gels. After electrophoresis, dried
gels were exposed to X-ray films at room temperature. Tumours
were scored according to the number of unstable mononucleotide
and dinucleotide microsatellites, and MS status was defined as
MSS for tumour displaying less than 10% of unstable loci and
MSI for tumour displaying more than 10% of unstable loci.
DNA analysis of hMSH2 and hMLH1 genes
Genomic DNA was isolated from blood samples or lymphocytes.
DNA was PCR-amplified for single-strand conformation polymor-
phism (SSCP) analysis of hMSH2 and hMLH1 coding sequences.
The reaction mixture (20 ml) contained 100 ng of genomic DNA,
0.15 mM of each primer (forward and reverse primers were located
in the sequences of the intron–exon boundaries of the hMSH2 and
hMLH1 genes, kindly provided by B Vogelstein, Johns Hopkins
University, and R Kolodner, Dana-Farber Cancer Institute; primers
are available upon request), 5 mM of each dNTP, [a33P]-dATP, 1.25
mM MgCl2, 1 ´ PCR buffer and 0.5 U Taq Polymerase (Perkin-
Elmer). PCR was performed as follows: one initial denaturing step
at 95°C for 5 min; 35 cycles at 95°C (1 min), 55°C (1 min) and
72°C (1 min); a final extension step at 72°C for 10 min. PCR prod-
ucts were diluted tenfold with formamide dye solution, followed
by denaturation at 95°C (2 min). SSCP analysis was performed as
previously described (Soufir et al, 1998). Aberrant single-strand
DNA fragment samples were analysed by direct sequencing. 
PCR products were purified with Microspin columns S-400HR
(Pharmacia) and sequenced with the Thermosequenase kit
(Amersham), following manufacturer’s instructions. Primers for
sequencing were the same as those used for PCR-SSCP.
Total RNA was isolated from lymphocytes or lymphoblastoid
cell lines using RNA-B™ (Bioprobe) according to the manufac-
turer’s instructions. cDNAs were reverse transcribed as previously
described (Soufir et al, 1998). One microlitre of cDNA templates
was PCR-amplified in a final volume of 50 ml as follows: 7.5 pmol
of each primer, 200 mM of each dNTP (Pharmacia), 1.5 mM MgCl2
and 1.25 U Taq Gold Polymerase (Perkin-Elmer). Primers are
available upon request. The PCR products were submitted to elec-
trophoresis on agarose gel and visualized by ethidium bromide
staining to check for the presence of abnormal bands.
For six cases, somatic allelic losses were assessed by comparing
sequencing data of matched lymphocytes and tumoural-extracted
DNA at the site of the germline missense hMLH1 mutations.
Experiments were performed four times using either dye primers
or dye dideoxynucleotides sequencing kits on both strands and
sequencing patterns were reproducible.
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Immunoperoxidase staining for hMLH1, hMSH2 and p53 proteins
in formalin-fixed, paraffin-embedded or frozen tissue sections,
was performed by a streptavidin–biotin diaminobenzidine tech-
nique as previously described (Gompel et al, 1994). Briefly, slides
were incubated overnight at 4°C with mouse monoclonal anti-
bodies to hMLH1 (clone Ab-1, 10 mg ml–1, Oncogene Research
Products) or hMSH2 (clone FE11, 5 mg ml–1, Oncogene Research
Products) or p53 (clone DO7, 2 mg ml–1, Dako). For frozen
sections, immunohistochemical analysis was performed with
antibodies at 5 mg ml–1 for hMLH1 and 2 mg ml–1 for hMSH2, 
1 mg ml–1 for p53. Normal tissue adjacent to tumour was used as
internal positive control. The normal staining pattern for both
hMLH1 and hMSH2 was nuclear. Tumour cells that exhibited an
absence of nuclear staining in the presence of non-neoplastic cells
with nuclear staining were considered to have an abnormal pattern.
Inversely, normal cells displayed no p53 staining, whereas nuclear
staining was a feature of tumoural samples.
RESULTS
Clinical features of CRC patients
In our three groups, cancer site and age at diagnosis were recorded
for each patient, as well as family history of CRC and cancers at
other sites (Table 1).
Microsatellite instability
First, we looked for microsatellite instability in tumours developed
by patients. Fifteen cases were stated as MSI and 19 cases were
stated as MSS (Table 2). Two cases (CHO and SCA) displayed
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Table 1 Clinical features of CRC patients
Patient Cancer site CRC in Cancers at other
identity and age at diagnosisb,c the familyd sites in the family
HNPCC
AUB R* (47) 3 Lung
HAL L (45); E* (48) 3 E
JEN R* (42); L (43) 4 E
GRI R* (26) 4 E
DUV L* (29) 5 Ovary
BLA E (54); R* (55); Bl (55); Ba (47;57) 3 E, breast
BES R* (55), L (55) 3 0
CHO R, L, Re* (31) 3 0
BIL Re (36), R* (42) 4 Lung, Ke, Sp
RIE R* (35) 3 E
Incomplete HNPCCa
BAR L* (52) 3 Breast
FAR L* (48) 2 Pancreas
PLO T* (37) 2 E
CHI L (57); R* (66) 2 St, sarcoma
MAL E (48); Re (56); R (63); L (65); T* (67) 2 E, breast, Ba
MER R* (52), E (52) ? ?
SCA Re* (50); St (50) 2 Lung, gynaecological
Sporadic CRC
DAC R* (17) 0 0
FRO Re* (20) 0 Lung, breast
DEL L (25); Re* (26) 0 0
DON T (28); L* (31) 0 0
GAN Re* (32) 0 0
VIT R* (34) 0 Prostate, brain
COU L* (42) 0 Breast
MEN L* (35) 0 E, prostate, ORL
HUC Re* (36) 0 Breast
CHA L* (37) 0 Breast, lung, testis
SKO L* (38) 0 0
CAM L* (41) 0 0
PER L* (42) 0 Lung
BEL L* (44) 0 0
LAM T* (44) 0 0
DES L* (47) 0 0
DAS Re* (50) 0 ?
a Missing ICG-HNPCC criterion: (i) only two relatives have colorectal cancer (FAR, PLO, CHI, MAL,
SCA); (ii) in one of the relatives, colorectal cancer was diagnosed after 50 years of age (BAR).
Abbreviations are R: ascendant colon; L: descendant colon and sigmoid; T: transverse colon; E:
endometrium; Re: rectum; St: stomach; Ke: keratoacanthoma; Sp: spino-cell carcinoma; Ba: basal
cell carcinoma. c Tissue studied for MS analysis and immunostaining are noted *. d Up to the second
degree for sporadic cases.MSI values of 28% and 17% respectively, below the 20–30% cut-
off used usually to define MSI (Bocker et al, 1997; Dietmaier et al,
1997). We classified these two cases as MSI because they
presented clear instability of mononucleotide (A)n repeats (3/3
and 2/3 respectively) whereas none of the 19 MSS cases displayed
any instability of the three mononucleotide (A)n repeats tested
(data not shown).
Analysis of MS status according to patient’s group showed a
clear-cut distribution, 15 out of 17 (88%) of HNPCC and incom-
plete HNPCC cases were MSI, whereas all 17 early-onset sporadic
cases (100%) were MSS (Table 2). The sensitivity of MSI detec-
tion is 88% (95% confidence interval (CI) 56–99%) and its speci-
ficity is 100% (80–100%).
Germline mutation of hMSH2 and hMLH1 genes
We screened for hMSH2 and hMLH1 germline mutations in all 15
MSI cases as well as in nine MSS cases, including seven cases
selected among the early-onset sporadic group. We detected five
non-ambiguous germline mutations (frame-shift or splice site) in
HNPCC or incomplete HNPCC cases (Tables 2 and 3). In addi-
tion, we detected five mis-sense mutations in hMLH1 gene and
one in hMSH2 gene. Screening for abnormally-sized cDNA
allowed us to detect deletion of exon 13 in hMSH2 gene from
patients BIL and COU which correspond to an alternative tran-
script (Xia et al, 1996; Mori et al, 1997) and deletion of exon 17 of
hMLH1 gene from patients CHI and SCA. In the case of CHI, loss
of exon 17 may be explained by the existence of a genomic mis-
sense mutation, Glu663Gly, this codon being the last one of exon
17. In the SCA case, no underlying genomic mutation was
detected by our screening methods. This exon skipping may be
non-pathogenic as an exon 17 splice variant was first reported in a
patient displaying an hMLH1 exon 15 splice donor site mutation
(Kohonen-Corish et al, 1996) and subsequently in 15/15 PBMC
samples (Genuardi et al, 1998b). We observed loss of hMLH1
expression in the tumour developed by patient SCA (Table 3),
which can be the consequence of hMLH1 gene somatic inactiva-
tion by mutation or hypermethylation (Thibodeau et al, 1996;
Kane et al, 1997). We also performed an SSCP screening for all
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Table 2 Microsatellite markers analysis, MMR status (genes and proteins) and p53 protein alterations
Patient Total MSI MS status Geneb hMSH2 proteinc hMLH1 proteinc p53 statusc,d
HNPCC
AUB 16/18 (89%) + hMLH1? NT NT NT
HAL 0/21 (0%) – None + + –
JEN 7/7 (100%) + None + + +
GRI 12/17 (70%) + None + – –
DUV 6/7 (86%) + hMLH1 + – –
BLA 6/7 (86%) + hMSH2 – + –
BES 16/23 (70%) + hMLH1 + + –
CHO 5/18 (28%) +a None – + –
BIL 12/15 (80%) + hMSH2 + + –
RIE 3/5 (60%) + hMLH1 NT NT –
Incomplete HNPCC
BAR 1/23 (4%) – None + + +
FAR 12/15 (80%) + None + – –
PLO 21/23 (91%) + hMSH2 – + –
CHI 10/17 (59%) + hMLH1 + – –
MAL 6/7 (86%) + hMLH1 + – –
MER 18/23 (78%) + None + – –
SCA 4/23 (17%) +a None + – –
Sporadic CRC
DAC 0/23 (0%) – None + + +
FRO 0/10 (0%) – None + + +
DEL 0/23 (0%) – None + + +
DON 0/23 (0%) – None + + +
GAN 0/20 (0%) – None + + +
VIT 1/24 (4%) – None + + –
COU 1/20 (5%) – None + + +
MEN 0/23 (0%) – NT + NT NT
HUC 1/24 (4%) – NT ND ND +
CHA 0/23 (0%) – NT + + NT
SKO 0/23 (0%) – NT + + NT
CAM 0/22 (0%) – NT + + +
PER 0/23 (0%) – NT + + +
BEL 0/23 (0%) – NT + + +
LAM 0/19 (0%) – NT + + +
DES 0/21 (0%) – NT + + +
DAS 0/23 (0%) – NT + + +
a These two cases were classified as MSI because they presented a clear instability of mononucleotide (A)n
repeats (3/3 and 2/3, respectively) whereas none of the 19 MSS cases displayed any instability of the 3
mononucleotide (A)n repeats tested (data not shown). b See details of germline mutations on Table 3. c NT: not
tested; ND: not determined, in relation with data of insufficient quality. d p53 status: negative, <10% positive
nuclear staining cells; positive > 40% positive nuclear staining cells.mis-sense mutations in a control population of 96 unrelated indi-
viduals belonging to families with inherited predisposition to
breast/ovarian cancers, melanoma or polyposis except HNPCC
families. All samples displaying abnormal migration pattern were
used as positive SSCP controls. Results are indicated in Table 3.
None of the mis-sense mutations were detected in the 96 unrelated
controls. For family BIL, we were able to perform segregation
analysis and we detected hMSH2 Gly751Arg germline mutation in
3/3 affected members and not in five unaffected members (data not
shown). In the four other cases, segregation analysis was not
possible. In 14 patients, neither hMSH2 nor hMLH1 germline muta-
tions were detected, nine were MSS and five were MSI cases. These
negative results are likely to be underestimated because we did not
search for either gross genetic abnormalities or inferred regulatory
mutations in hMSH2 and hMLH1 genes, or for any kind of alter-
ations in PMS1, hPMS2, hMSH6/GTBP and TGFbRII genes.
Tumoural LOH for validation of mis-sense mutations
Overall, we detected six germline missense mutations and in the
absence of a functional test, we had difficulties in discriminating
between variants and disease-causing mutations for five of them.
Except in rare cases of dominant mutations, deleterious mis-sense
mutations in tumour suppressor genes are followed by a second
somatic event acquired in tumoural cells such as allelic loss, point
mutation or hypermethylation. In order to detect tumoural loss of
heterozygosity (LOH), we performed automated sequencing of
DNA extracted from microdissected tumours at the site of five
germline mis-sense mutations using a positive control with unam-
biguous mutation (MAL patient). Four cases (MAL, CHI, AUB,
BES) showed a decrease of wild-type allele in tumoural DNA as
compared to lymphocyte-extracted DNA, whereas two cases
(CHO and DAC) had identical sequencing patterns in lymphocyte
and tumour-extracted DNA (Figure 1). These results showing loss
of hMLH1 wild-type allele in three tumours in addition to the
positive control, argue for a pathogenetic role for Glu663Gly,
Val716Met and Thr117Met mutations. In addition, Thr117Met
scored as a loss-of-function mutation in a functional assay
(Shimodaira et al, 1998). The significance of hMLH1 Val716Met
germline mis-sense mutation still remains uncertain because it was
detected in two patients with MSS tumour (Genuardi et al, 1998a;
S Olschwang, personal communication). This mutation could be
non-pathogenic and the hMLH1 tumoural LOH that was observed
could be related to unidentified hMLH1 germline or somatic
events. No tumoural LOH was seen for Val326Ala and His718Tyr
mutations. Kowalski et al found an allele frequency of 0.14 for
His718Tyr among an Afro-American population (Kowalski et al,
1997), suggesting that this mutation represents a polymorphism.
hMLH1 Val326Ala did not score as a loss-of-function mutation in
a functional assay and therefore is likely to be a rare variant
(Shimodaira et al, 1998). Overall, in the absence of a functional
test and segregation analysis (no living affected relatives exist in
severely affected HNPCC families), the analysis of second somatic
events in the tumoural DNA is valuable in order to classify mis-
sense mutations as simple variants or disease-causing mutations.
Correlation of hMSH2 and hMLH1 protein expression
with MS status and germline mutations
Protein expressions were examined in patients’ tumours. Lack of
hMLH1 or hMSH2 expression was observed in ten tumours, all of
them being MSI and removed from family cases (HNPCC or
incomplete HNPCC) (Table 2 and Figure 2). No cases had
concomitant loss of hMSH2 and hMLH1. All sporadic MSS
tumours tested (15 cases) displayed normal staining pattern for
hMLH1 and hMSH2. The absence of one of the two MMR gene
products was associated with the presence of a validated germline
mutation in the corresponding gene in five cases (DUV, BLA,
Molecular screening for HNPCC 875
British Journal of Cancer (2000) 82(4), 871–880 © 2000 Cancer Research Campaign
Table 3 Validation of hMSH2 and hMLH1 germline mutations
Patient Gene Exon Codon Nucleotide Consequenceb Tumoural Segregation Controlsc Published Loss of Conclusion
changea LOH mutationd functione
AUB hMLH1 19 716 G2146A Val 716 Met Loss WT Yes, 2 cases 0/192 Yes1 NT Uncertain 
significance
DUV hMLH1 Intron 6 – A546-2G Deletion exon 7 NT Yes, 5 NT Yes1 NT Mutation
cases
BLA hMSH2 5 280 840insT Frame-shift NT Yes, 2 cases NT Yes2 NT Mutation
BES hMLH1 4 117 C350T Thr 117 Met Loss WT NT 0/192 Yes1 Yes Mutation
CHO hMLH1 19 718 C2152T His 718 Tyr none NT 0/192 Yes1 NT Likely 
polymorphism
BIL hMSH2 14 751 G2251A Gly 751 Arg NT Yes, 3  0/192 No NT Likely mutation
cases
RIE hMLH1 11 332 994delA Frame-shift NT Yes, 3  NT No NT Mutation
cases
PLO hMSH2 15 828 dup 14bp2484 Frame-shift NT Yes, 2  NT No NT Mutation
cases
CHI hMLH1 17 663 A1988G Glu663Gly/deletion exon 17 Loss WT NT 0/192 No NT Mutation
MAL hMLH1 Intron 14 – C1668-3A NT Loss WT NT NT No NT Mutation
SCA hMLH1 NI Deletion exon 17 NT NT NT No NT Splice variant
DAC hMLH1 11 326 T977C Val 326 Ala none NT 0/192 Yes1 No Polymorphism
a NI: not identified by the available techniques. b NT: not tested. c Allele frequency in control chromosomes from 96 unrelated individuals. d1 Mutation reported in
the ICG-HNPCC database (http://www.nfdht.nl) and/or the literature; 2mutation already published by the authors. e Reference: Shimodaira et al (1998).PLO, CHI and MAL), but not in four cases without detected
germline mutation. In these four cases, the observed loss of
hMSH2 or hMLH1 expression could be related to inferred regula-
tory germline mutation, somatic mutation and in addition, for
hMLH1 to promoter hypermethylation (Herman et al, 1998). It
should be noticed that cases BES and BIL have validated hMSH2
or  hMLH1 mis-sense germline mutations (Glu751Arg and
Thr117Met respectively) and normal hMSH2 and hMLH1 expres-
sion in their tumour. As previously stated, mis-sense mutations
might give rise to normal levels of a non-functional protein
(Thibodeau et al, 1996). Indeed, the hMSH2-deficient ovarian
tumour cell line 2774, despite the presence of an Arg524Pro mis-
sense mutation in exon 14 of hMSH2 gene, produces a full-length
mutant protein (Orth et al, 1994; Richards et al, 1997).
Correlation of p53 protein expression with MS status
and hMSH2/hMLH1 germline mutations
We also explored p53 status in our three groups of patients. There
is a good correlation between p53 gene mutations and p53 protein
accumulation at a cellular level (Casey et al, 1996), therefore we
examined p53 protein expression in all available samples. In some
cases, tumoural tissues were totally consumed by previous experi-
ments and p53 status could not be determined. Independently to
molecular results, p53 staining was first scored by a pathologist in
four categories: –, no staining; +, 0–10% positive cells; ++,
10–50% positive cells; +++, 50–100% positive cells (data not
shown). At a second examination, it was noticed that all + cases
were 0–5% positive cells, whereas ++ cases were 40–50% positive
cells. Therefore, a final p53 status was given, negative for tumours
displaying less than 5% nuclear p53 staining cells and positive for
tumours displaying more than 40% nuclear p53 staining cells
(Table 2). Negative p53 staining was detected in all family cases
tumours, mainly MSI, except two (JEN and BAR); positive p53
staining was detected in all sporadic cases which are also MSS
tumours, except one (VIT). Examples are shown in Figure 2. The
proportion of MSI and p53 negative staining was 81% (13/16)
among family cases (HNPCC and incomplete HNPCC) and 0%
(0/14) among sporadic CRC (Fisher’s exact test, P < 0.00001).
DISCUSSION
In order to identify hereditary CRC, we performed combined
molecular approaches among three different groups, HNPCC
kindreds fulfilling the ICG criteria, families in which at least one
of the criteria was not satisfied and apparently sporadic CRC cases
diagnosed before the age of 50.
Analysis of MS status in relation with patient’s groups showed a
clear-cut distribution, 15 out of 17 (88%) of HNPCC and incom-
plete HNPCC cases were MSI, whereas all 17 early-onset sporadic
cases were MSS. This observation of absence of MSS sporadic
tumours in our series is not in accordance with other reported
studies. The 17 sporadic cases with early onset were selected
prospectively upon precise criteria (age being below 50 years at
diagnosis of CRC; absence of any CRC and tumours from the
HNPCC spectrum recorded in their families up to the second
degree) in a clinic-based population. MMR deficiency based on an
MSI status has been reported in sporadic CRC at varying
876 B Dieumegard et al
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Figure 1 Analysis of tumoral LOH at germinal mutation sites for six cases. For each patient, three sequencing patterns are shown, a wild-type control (C),
patient’s lymphocytes (L) and tumour (T). Germline mutations are described, codons (above) and arrows point to the exact mutated nucleotides (beneath). From
upper left to lower right: four cases (MAL, CHI, AUB, BES) show a decrease of wild-type allele in tumoural DNA, whereas two cases (CHO and DAC) have
identical sequencing patterns in lymphocytes and tumour-extracted DNAMolecular screening for HNPCC 877






Figure 2 Immunohistochemical detection of hMSH2 in normal colonic epithelium (A) and absence of staining of epithelial neoplastic cells (B) for patient BLA;
immunohistochemical detection of hMLH1 in normal colonic epithelium (C) and absence of staining of epithelial neoplastic cells (D) for patient GRI; absence of
p53 staining in an MSI adenocarcinoma, patient BLA (E) and positive staining in an MSS adenocarcinoma, patient DON (F)frequency in several studies: 13% of 273 samples (compiled data
in Kinzler and Vogelstein, 1996), 36% of 77 samples (Liu et al,
1995a) and 15% of 88 samples (Olschwang et al, 1997). In these
earlier studies, selection against family history was less stringent
than in our study, in which only CRC cases from HNPCC families
according to ICG criteria were excluded. Therefore, an unknown
fraction of these tumours could have been stated as incomplete
HNPCC according to our criteria and might represent false
sporadic cases. Additionally, sporadic CRC cases might have been
selected upon additional criteria, such as CRC location, among a
large population of sporadic CRC. Indeed, in another study
describing 19 sporadic MSI CRC, some of which displayed
somatic hMSH2 mutations, 18 were right-sided (Borresen et al,
1995). In our series of 17 sporadic CRC cases only two tumours
were right-sided. Therefore, tumour location in colon may partly
explain differences between our results and previously reported
frequent sporadic MSI CRC. Moreover, a model explaining the
relationship between MMR genes dysfunction and tumour loca-
tion in right colon has been recently proposed (Janin, 1999).
The absence of MSI among 17 early-onset sporadic cases indi-
cates that MMR genes inactivation, either germline or somatic, is a
rare event in sporadic CRC. Concerning germline mutations, a 6%
(3/50) prevalence of hMSH2 and hMLH1 germline mutations was
reported in a cohort of CRC cases diagnosed before the age of 45
and without a family history of any HNPCC cancers (Tomlinson et
al, 1997). This prevalence may have been overestimated because
the three germline mutations detected were mis-sense, one at least
being a known polymorphism (hMLH1, Ile219Val) (Liu et al,
1995b). Therefore, genetic susceptibility other than MMR gene
germline mutations and/or environmental factors are responsible
for the majority of CRC developed by young patients (reviewed in
Burt, 1996). In addition, although our series is small and some
MMR gene somatic mutations have been reported (Borresen et al,
1995; Thibodeau et al, 1996), our results (i.e. 17 sporadic tumours
displaying MSS and hMSH2/hMLH1 protein immunostaining)
indicate that somatic inactivation of hMSH2 and hMLH1 genes is
not a frequent event in sporadic colorectal carcinogenesis, at least
for patients younger than 50. Therefore, colorectal tumorigenesis
may represent a second example of the existence of two different
genetic pathways for sporadic and inherited cancers, after the
breast and ovarian cancer model (Futreal et al, 1994; Merajver et
al, 1995).
The second point addressed in this work was to explore p53
status in relation with the MMR pathway status. We examined p53
protein expression in all available tumoural tissue samples by
immunohistochemistry. Negative p53 staining was detected in all
family cases tumours, mainly MSI, except two, and positive p53
staining was detected in all sporadic and MSS tumours except one.
Similar correlation has recently been reported (Fujiwara et al,
1998).  p53 gene somatically-acquired mutations occur very
frequently during the development of CRC (Baker et al, 1989).
Such mutations lead to p53 protein accumulation probably in rela-
tion with loss of mdm2-mediated down-regulation (Midgley and
Lane, 1997). Absence of p53 staining in MSI tumours could be
related to (i) accumulation of multiple p53 mutations leading to
the absence of p53 protein and (ii) wild-type p53 protein. Several
studies reporting low incidence of p53 mutation in MSI tumours
imply that the second hypothesis may be relevant for the majority
of MSI/p53- cases (Ionov et al, 1993; Losi et al, 1997; Olschwang
et al, 1997). The significant correlation that we observed between
microsatellite status and p53 protein accumulation may have a
molecular explanation. Two alternative genetic pathways have
been described in colorectal carcinogenesis, with either APC gene
or MMR gene inactivation (Olschwang et al, 1997). In the APC
pathway, the defective APC protein is unable to promote the
proteolytic degradation of b-catenin, leading to its accumulation
(Munemitsu et al, 1995) and it has been recently reported that
overexpression of b-catenin results in accumulation of p53,
possibly through interference with its proteolytic degradation
(Damalas et al, 1999). Therefore, the correlation between MSS
(absence of MMR gene inactivation and probable APC gene
inactivation) and p53 protein accumulation, makes sense.
To summarize, 13 out of 16 (81%) family cases were MSI and
p53 protein-negative, whereas 13/14 (93%) sporadic cases were
MSS and p53 protein-positive. Such observations support the
concept of the existence of two different genetic pathways in
colorectal carcinogenesis (Olschwang et al, 1997). The first
pathway exists mainly in family cases and is characterized by
MMR gene inactivation without p53 protein accumulation. The
second, which is more frequent in sporadic cases, is characterized
by p53 protein accumulation without MMR gene inactivation.
Therefore, simple tests performed on tumoural tissues, such as MS
study combined with hMSH2 and hMLH1 protein immuno-
staining, provide valuable information to select cases relevant to
germline mutation screening.
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